As the number of antimicrobial-resistant infections worldwide is growing exponentially, the need for feasible and effective alternatives to antibiotics has skyrocketed. Drug developers are combating antibiotic resistance by translating bacteriophages into robust clinical candidates and are navigating the regulatory challenges with GMP manufacturing.
The 7th Bacteriophage Therapy Summit united industry leaders, such as Armata Pharmaceuticals, Phiogen Pharma, and TechnoPhage as they shared clinical data, dove into the investment opportunities for bacteriophage companies, and tackled the regulatory challenges in development.
What You Missed:
Targeting bacterial infections rapidly with personalized and off-the-shelf bacteriophages with wide coverage of strains with Kinzbio, Cytophage and PhagePro
Supercharging the investment opportunities for bacteriophage companies to proceed to the clinic and prove viability as an alternative to antibiotics with BARDA, Sozo Ventures, and Phiogen Pharma
Discovering the most recent updates from pivotal phase II clinical trials with Armata Pharmaceuticals as they moved beyond compassionate use of bacteriophages to fight AMR bacteria
Accomplishing market approval for bacteriophage therapies by diving into the current regulatory guidelines with TechnoPhage and Precisio Biotix Therapeutics
Achieving sustainable commercialization of bacteriophages post-approval, with a reimbursement strategy with Cytophage and PhagePro
